Kisspeptin-10: A Real Hormone Switch With Thin Human Evidence

Kisspeptin-10 is in an unusual spot. It’s a real, well-studied piece of a natural hormone with genuine human data behind it, not a made-up molecule invented for a supplement label. Inject it into the right person at the right time, and reproductive hormones reliably climb. That part is solid. But the impressive clinical results people point to when they sell kisspeptin online, like risk-free IVF triggering and a boost in sexual desire, came from a different, longer-lasting molecule called kisspeptin-54. For Kisspeptin-10 itself, the human evidence is small, brief, and limited to hormone readings rather than real-life results. This profile keeps those two molecules carefully apart.

What it is

Kisspeptin-10 (Kp-10) is a decapeptide, which just means it’s a short chain of ten amino acids (the building blocks of proteins). Its sequence is Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe, finished off with an amide cap (a chemical end-piece). It’s the shared core of the bigger kisspeptin family (kisspeptin-54, -14, -13 and -10), matching residues 45–54 of kisspeptin-54. It belongs to a group called the RFamide peptides, and that final arginine-phenylalanine-amide tail is what lets it switch on its target. Structural studies show the molecule forms a short coiled (helical) section near its tail end. In alanine-scanning experiments (a method that swaps one amino acid at a time to see which ones matter), swapping position 6 dulls the response, while swapping position 10 wipes it out completely and breaks that coil.

Here’s how it works. Kp-10 latches onto KISS1R (a receptor, or docking site, once called GPR54) that sits on GnRH neurons (specialized nerve cells in the hypothalamus, the brain’s hormone control center). When it docks, it fires up those neurons and triggers pulses of GnRH (gonadotropin-releasing hormone). GnRH then tells the pituitary gland to release luteinizing hormone (LH, the strongest effect) and follicle-stimulating hormone (FSH). Those two hormones, in turn, prompt the gonads (testes or ovaries) to make sex hormones such as testosterone. We now understand kisspeptin signaling as the master switch at the very top of this chain, controlling both puberty and adult reproduction. Without it, the whole system never gets going.

One naming warning: “metastin” and “kisspeptin-54” both refer to the larger 54-amino-acid version, not to Kp-10. They’re related but not interchangeable, and the difference matters when you’re reading the evidence.

The claims

In real research, Kp-10 is used as a quick stimulation test for the reproductive hormone system, and as a tool to study how GnRH pulses are made, how puberty starts, and what goes wrong in conditions like hypogonadism (low sex-hormone output) and hypothalamic amenorrhea (missed periods caused by a brain-signal problem).

The bigger drug-development goals, like an IVF egg-maturation trigger that avoids ovarian hyperstimulation syndrome (a dangerous over-response of the ovaries), treatments for hypothalamic amenorrhea, diagnostic testing of the hormone system, and therapy for low sexual desire, have mostly been chased with kisspeptin-54, not Kp-10.

Then gray-market marketing piles on consumer claims that go far past anything the Kp-10 data actually shows: raising testosterone or libido, acting as a “natural” stand-in for testosterone replacement or for clomiphene/enclomiphene (prescription drugs that nudge the body’s own hormone output), boosting fertility, or restarting the hormone system after anabolic steroid use. None of these consumer promises are backed by outcome trials of Kisspeptin-10.

The evidence

The honest summary: Kp-10 does exactly what its biology predicts in short human experiments, and nothing beyond that has been proven.

Human data on Kisspeptin-10 specifically. George and colleagues (Journal of Clinical Endocrinology & Metabolism, 2011) gave Kp-10 to healthy men intravenously (into a vein), both as quick single shots and as a steady drip. The steady drip raised average LH, how often LH pulsed, how big those pulses were, and testosterone, and it was well tolerated with no significant side effects. The effect is real, but the group was tiny and the dosing was brief. Jayasena and colleagues (also JCEM, 2011) showed the response differs by sex (sexually dimorphic): Kp-10 raised LH and FSH in men even at low doses; it did not raise these hormones in women during the follicular phase (the first half of the menstrual cycle) even at high doses, but it did raise them in women during the preovulatory phase (just before an egg is released). So the effect depends on sex and on where someone is in their cycle.

The kisspeptin-54 context, which is not Kp-10 evidence. The landmark first-in-human study (Dhillo et al., JCEM 2005) that raised LH, FSH and testosterone in men used kisspeptin-54, as its own title says. The promising IVF work, an open-label Phase 2 trial in 60 women at high risk of ovarian hyperstimulation (Abbara et al., JCEM 2015) and a follow-up randomized second-dose trial in 62 women (Abbara et al., Human Reproduction 2017), used kisspeptin-54. So did the two crossover randomized trials in low sexual desire published in JAMA Network Open (32 premenopausal women in 2022; 32 men in 2023, where penile tumescence rose up to 56% over placebo). These are interesting results, but pinning them on Kisspeptin-10 is simply wrong.

Animal data. Across many species, kisspeptin (including Kp-10) drives the release of GnRH and LH, and losing the gene or the receptor causes failure of puberty and hypogonadotropic hypogonadism (low sex hormones because the brain’s signal is missing). The mechanism is well established in animal studies.

What’s missing, and the skeptical read. There are no randomized clinical-outcome trials for Kp-10 itself; every Kp-10 human study is brief and stops at biomarkers (hormone measurements in the blood). Almost all human kisspeptin trials come from a single group at Imperial College London, so there’s little independent confirmation from other labs. Several trial authors disclosed consulting fees from Myovant Sciences, and one was employed by Invicro; funding came from the UK’s NIHR and Medical Research Council. The biggest practical hurdle is how fast the body clears it: Kp-10’s terminal half-life (the time for blood levels to fall by half once they start dropping) is roughly four minutes, versus about 28 minutes for kisspeptin-54, and a continuous drip causes the receptor to stop responding, an effect called desensitization or tachyphylaxis (the body tuning out a repeated signal). That’s exactly why developers switched to the longer-lasting kisspeptin-54. A 2025 systematic review (Velmurugan et al., Current Medicinal Chemistry) covered 29 interventional trials but framed mostly small, early-stage studies in an upbeat way and made no claim about regulatory approval, so read it with that in mind.

Safety and side effects

In short, controlled research settings, single brief doses of Kp-10 (and of kisspeptin-54) were generally well tolerated, and the trials above reported no significant side effects.

The catches are big, though. There’s no long-term human safety data for Kp-10; every trial has been brief, so we simply don’t know how ongoing use would affect the hormone system, bones, mood, or the heart and blood vessels. Tachyphylaxis (the body tuning out the signal) with continuous dosing is a known drawback. Tinkering with the reproductive hormone system without medical supervision carries theoretical risks of disrupted cycles, unpredictable hormone swings, and interactions with fertility treatments. And because gray-market material is sold as a “research chemical, not for human use,” its quality, including purity, sterility (freedom from germs), and endotoxin content (bacterial contamination that can cause fever or worse), is a separate hazard with no one checking it.

Legal and regulatory status

Kisspeptin-10 is not approved by the FDA, or any other regulator, for any use; it’s still investigational. On October 29, 2024, the FDA’s Pharmacy Compounding Advisory Committee voted against adding kisspeptin-10 to the 503A bulk-drug-substances list (the roster of ingredients pharmacies are allowed to compound from). It had been nominated for secondary hypogonadism in men, so compounded Kp-10 is not an FDA-sanctioned bulk substance. No marketing approval for kisspeptin in any form has been found anywhere in the world.

In sport, kisspeptin is banned. It was added as a named example to the 2024 WADA Prohibited List under category S2 (peptide hormones, growth factors, related substances and mimetics) as a testosterone-stimulating peptide, which means it’s prohibited at all times, both in and out of competition.

In practice, Kp-10 is sold online as a “research chemical,” with no one checking its identity, purity, or sterility, and with the one formal route toward compounded use having been specifically turned down.

Bottom line

Kisspeptin-10 is a legitimate research tool with a clear, proven mechanism: it raises reproductive hormones in short human studies, in a way that depends on sex and cycle timing. That’s the full extent of what’s been shown for this specific molecule. There are no trials proving it improves fertility, sexual function, or any other real-world outcome, and its very short half-life plus its tendency to make the receptor stop responding are exactly why drug developers preferred the related kisspeptin-54 instead. The eye-catching fertility and libido headlines belong to that other molecule and shouldn’t be read as evidence for Kp-10. It’s unapproved everywhere, turned down for compounding, and banned in sport. The honest grade is preliminary human: some real human data, all of it small, brief, and short.

Sources

• George et al., JCEM 2011 (Kp-10 in men)
• Jayasena et al., JCEM 2011 (sexual dimorphism of Kp-10)
• Dhillo et al., JCEM 2005 (kisspeptin-54, first human study)
• Structure-activity relationship study (Mol Pharmacol)
• Kisspeptin history and nomenclature (PMC review)
• KISS1R receptor pharmacology (Guide to Pharmacology)
• Abbara et al., JCEM 2015 (kisspeptin-54 IVF Phase 2)
• Abbara et al., Human Reproduction 2017 (second-dose RCT)
• Thurston et al., JAMA Network Open 2022 (women, HSDD)
• Mills et al., JAMA Network Open 2023 (men, HSDD)
• Velmurugan et al., systematic review 2025
• FDA Pharmacy Compounding Advisory Committee, October 29, 2024 meeting
• FDA meeting materials
• PCAC votes against four nominated bulk drug substances
• USADA: key changes to the 2024 Prohibited List